Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 989 GBX 0.05%
Market Cap: 4.4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Gross Profit
$1.4B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
5%
GlaxoSmithKline PLC
LSE:GSK
Gross Profit
ÂŁ22.9B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Gross Profit
$40.4B
CAGR 3-Years
22%
CAGR 5-Years
17%
CAGR 10-Years
7%
Verona Pharma PLC
NASDAQ:VRNA
Gross Profit
$5.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Gross Profit
$952m
CAGR 3-Years
16%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Dechra Pharmaceuticals PLC
LSE:DPH
Gross Profit
ÂŁ429.6m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
16%
No Stocks Found

Hikma Pharmaceuticals PLC
Glance View

Market Cap
4.4B GBX
Industry
Pharmaceuticals

Hikma Pharmaceuticals PLC, a Jordanian-British multinational, began its journey in the heart of Amman, Jordan, in 1978, founded by Samih Darwazah. Over the years, it has evolved from a local pharmaceutical manufacturer into a global powerhouse, recognized as a key player in the generic pharmaceutical industry. The company's core strategy revolves around the production and distribution of a wide array of generic medications, serving diverse therapeutic categories such as cardiovascular, oncology, and infectious diseases. Hikma's competitive edge lies in its ability to produce high-quality and cost-effective medicines, which are crucial in both high-demand regions and emerging markets where affordable healthcare options are often limited. By leveraging its robust manufacturing capabilities and regulatory expertise, Hikma efficiently supplies generic and branded medications to over 50 countries worldwide, nurturing its growth and bolstering its market position. Driving the gears of Hikma's revenue machine are its three main operational segments: Injectables, Generics, and Branded pharmaceuticals. The Injectables division, a significant contributor to its financial health, supplies hospitals with critical sterile products, benefiting especially when acute care needs surge. Meanwhile, the Generics division continues to expand its footprint in the U.S. market, offering cost-effective alternatives to brand-name drugs, riding the wave of patent expirations. The Branded segment, deeply rooted in the Middle East and North Africa, capitalizes on Hikma's regional expertise and trusted brand reputation. Through this diversified business model, Hikma not only fortifies its financial stability but also ensures resilience against market fluctuations, steering the firm towards sustainable growth amidst an ever-evolving global pharmaceutical landscape.

HIK Intrinsic Value
3 871.5 GBX
Undervaluation 49%
Intrinsic Value
Price

See Also

What is Hikma Pharmaceuticals PLC's Gross Profit?
Gross Profit
1.4B USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Gross Profit amounts to 1.4B USD.

What is Hikma Pharmaceuticals PLC's Gross Profit growth rate?
Gross Profit CAGR 10Y
5%

Over the last year, the Gross Profit growth was 4%. The average annual Gross Profit growth rates for Hikma Pharmaceuticals PLC have been 5% over the past three years , 5% over the past five years , and 5% over the past ten years .

Back to Top